Kisspeptin-10 Dosage, half-life & reference guide

Week by week.

What to expect in the first 8 weeks

1. Day 1–7Clinical

   Fast LH and testosterone surge

   Kisspeptin-10 works upstream of GnRH — the "wake-up call" of the HPG axis. In studies in men, LH rose within 30–60 min of a dose, with testosterone following over a few hours. Commonly reported: a mood, libido or energy lift within the first few doses for some; many find it subtle.

   The science

   Kisspeptin-10 activates KISS1R (GPR54) on hypothalamic neurons, triggering GnRH release upstream of the pituitary. Dhillo et al. 2005 (kisspeptin-54) and George et al. 2011 (kisspeptin-10) showed LH rising within 30–60 minutes in men, with testosterone following. Phase 2 trials in hypogonadism and hypothalamic amenorrhea are recruiting.

   Sources

   • Dhillo et al. (2005)
   • George et al. (2011)

   Updated Sep 2026

2. Day 7–28Clinical

   HPG axis coming online

   Community protocols settle into 2–3x/week dosing here; no human study has tested that schedule. Kisspeptin-10 works one step upstream of gonadorelin: it prompts your own GnRH neurons to fire, so it relies on that part of the system still working (gonadorelin skips it and acts on the pituitary directly).

   The science

   In healthy men, daily 8-hour infusions of kisspeptin-10 for 12 days kept LH and FSH raised, while continuous infusion for 5 days let them fall back (Yeung 2026). In men with low sexual desire, a single infusion of the longer kisspeptin-54 boosted sexual-brain activity and erection response to erotic videos (Mills 2023). The kisspeptin → GnRH → LH/FSH cascade is the physiological upstream route, making kisspeptin a candidate for HPG axis restoration protocols.

   Sources

   • Yeung et al. (2026)
   • Mills et al. (2023)

   Updated Sep 2026

3. Day 28–84Clinical

   Assess labs, decide next step

   At 1–3 months, pull labs — total T, free T, LH, FSH. Kisspeptin-10 protocols are typically run in cycles until either the HPG axis restart is confirmed (post-cycle context) or ongoing use is decided (fertility context). Long-term chronic dosing data is limited.

   The science

   Human studies of kisspeptin-10 have been acute or short (up to 12 days); the longest repeated-dosing data are for kisspeptin-54 (twice weekly for 8 weeks in women with hypothalamic amenorrhea, with partial desensitization). Long-term safety and tachyphylaxis with chronic use aren't characterized. Cycle-and-reassess is the conservative approach.

   Sources

   • Yeung et al. (2026)
   • Jayasena et al. (2010)

   Updated Sep 2026

4. Any dayClinical

   What Kisspeptin-10 is built on

   Kisspeptin has genuine clinical trial evidence from the Dhillo group at Imperial College and others, mostly for the longer kisspeptin-54 form (IVF and low libido); kisspeptin-10's human data are shorter hormone-response studies, with fertility trials now recruiting. Not yet FDA-approved for any indication, but among the best-studied of the research-stage sexual health peptides.

   The science

   Active NIH clinical trials for hypogonadism and fertility indications. The kisspeptin system is itself a relatively recent discovery (KISS1/GPR54 identified as HPG axis regulator in 2003), which is why clinical use is still being characterized. Safety profile in completed trials has been clean; FDA lists kisspeptin-10 in compounding category 2.

   Sources

   • Dhillo et al. (2005)
   • George et al. (2011)
   • Mills et al. (2023)

   Updated Sep 2026

Swipe for more ›

Mixing and a typical run.

Safety.

Goes with.

• Gonadorelin
• PT-141

Questions people ask.

Research.

Reference.

Cadence

2–3× weekly

Pulsatile — 2–3x/week

Half-life

~4 min

~4 min (kisspeptin-54, a longer form, lasts ~28 min)

Research basis

●●● Emerging

Primarily preclinical / limited human data